APA (7th ed.) Citation

Fang, G., Pi, Z., An, Y., Cao, X., Li, W., Li, W., . . . Ding, J. Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Fang, Gang, Zhipeng Pi, Yiping An, Xinxin Cao, Wei Li, Wei Li, Xiangjun Zhu, Jinxi Ding, and Jinxi Ding. Cost-effectiveness Analysis of Gumarontinib Versus Savolitinib for the Treatment of Advanced or Metastatic NSCLC with MET Exon 14 Skipping Mutations in China Using Partitioned Survival Model. Frontiers Media S.A.

MLA (9th ed.) Citation

Fang, Gang, et al. Cost-effectiveness Analysis of Gumarontinib Versus Savolitinib for the Treatment of Advanced or Metastatic NSCLC with MET Exon 14 Skipping Mutations in China Using Partitioned Survival Model. Frontiers Media S.A.